Colas Tcherakian
University of Paris-Sud
60 Papers
114 Citations
Colas Tcherakian is an academic researcher from University of Paris-Sud. The author has contributed to research in topics: Medicine & Pulmonary hypertension. The author has an hindex of 14, co-authored 43 publications.
Chat about Author
Papers
Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension.
Frédéric Perros,David Montani,Peter Dorfmüller,Ingrid Durand-Gasselin,Colas Tcherakian,Jérôme Le Pavec,Michel Mazmanian,Elie Fadel,Sacha Mussot,Olaf Mercier,Philippe Hervé,Dominique Emilie,Saadia Eddahibi,Gérald Simonneau,Rogério Souza,Marc Humbert +15 more
TL;DR: PDGF may play an important role in human PAH and novel therapeutic strategies targeting the PDGF pathway should be tested in clinical trials.
477
Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases.
Xavier Jaïs,David Launay,David Launay,Azzedine Yaici,Jérôme Le Pavec,Colas Tcherakian,Olivier Sitbon,Gérald Simonneau,Marc Humbert +8 more
TL;DR: PAH associated with SLE or MCTD may respond to a treatment combining cyclophosphamide and glucocorticoids, and patients who could benefit from this immunosuppressive therapy could be those who have less severe disease at baseline.
400
Pulmonary Veno-Occlusive Disease Clinical, Functional, Radiologic, and Hemodynamic Characteristics and Outcome of 24 Cases Confirmed by Histology
David Montani,L. Achouh,Peter Dorfmüller,Jérôme Le Pavec,Benjamin Sztrymf,Colas Tcherakian,Anne Rabiller,Rehan Haque,Olivier Sitbon,Xavier Jaïs,Philippe Dartevelle,Sophie Maitre,Frédérique Capron,Dominique Musset,Gérald Simonneau,Marc Humbert +15 more
TL;DR: 2 additional cases of bone morphogenetic protein receptor II (BMPR2) mutations have been previously described in PVOD patients and are described in the current study, which compared clinical and radiologic findings, pulmonary function, and hemodynamics at presentation, as well as outcomes after the initiation of PAH therapy in both groups.
357
Pulmonary Langerhans Cell Histiocytosis-Associated Pulmonary Hypertension: Clinical Characteristics and Impact of Pulmonary Arterial Hypertension Therapies
Jérôme Le Pavec,Gwenaël Lorillon,Xavier Jaïs,Xavier Jaïs,Colas Tcherakian,Séverine Feuillet,Peter Dorfmüller,Peter Dorfmüller,Gérald Simonneau,Gérald Simonneau,Marc Humbert,Marc Humbert,Abdellatif Tazi +12 more
TL;DR: In this group of patients, PAH therapies improved hemodynamics without oxygen worsening or pulmonary edema, and the WHO functional class was the only variable significantly associated with death.
135
Rituximab for induction and maintenance treatment of ANCA-associated vasculitides: a multicentre retrospective study on 80 patients
Pierre Charles,Antoine Néel,Nathalie Tieulie,Arnaud Hot,Grégory Pugnet,Olivier Decaux,Isabelle Marie,Mehdi Khellaf,Jean-Emmanuel Kahn,Alexandre Karras,Jean-Marc Ziza,Christophe Deligny,Colas Tcherakian,Loïc Guillevin +13 more
TL;DR: Rituximab was able to induce AAV remission and seemed to maintain remission better than other agents, but caution is needed concerning its safety, especially regarding bacterial infections, in this population of patients.
125